A shocking revelation has come to light as dozens of patients are suing the maker of the popular weight loss drug, Ozempic, over claims of severe side effects. Novo Nordisk, the pharmaceutical company behind Ozempic and Wegovy, is facing a wave of lawsuits from patients who allege that the drugs caused them debilitating stomach paralysis, with some reporting lifelong consequences.

According to a DailyMail.com investigation, patients across America have experienced extreme side effects from using Ozempic and Wegovy, which they claim they were not adequately warned about. The lawsuits filed since November reveal harrowing stories of patients diagnosed with gastroparesis, a condition that can be life-threatening and leads to symptoms such as nausea, vomiting, and severe pain due to paralysis of the stomach.

One woman, Brea Hand, recounted her ordeal, stating that she required five hospital visits before being diagnosed with gastroparesis allegedly caused by Ozempic. Another patient, Zakareeya Gregory, spent four weeks in the hospital and had her gallbladder removed due to complications from using Ozempic.

The lawsuits uniformly accuse Novo Nordisk of failing to provide adequate warnings about the risk of gastroparesis associated with the drugs. The situation is further compounded by the fact that Eli Lilly, the maker of Mounjaro, a diabetes drug similar to Ozempic and Wegovy, is also facing at least ten lawsuits with similar claims about undisclosed side effects.

The severity of the reported side effects is alarming, with some patients claiming they will suffer from diarrhea for the rest of their lives. The legal campaign against the pharmaceutical companies is expected to grow, with attorneys stating that ‘thousands’ more lawsuits will be filed in the future.

This development raises serious concerns about the adequacy of warnings and information provided to patients regarding the potential risks associated with these weight loss drugs. As the legal battle unfolds, it remains to be seen how the pharmaceutical companies will address these allegations and what measures will be taken to ensure the safety of patients prescribed with these medications.